Combining CT scans and pathology slides to predict ovarian cancer treatment response
Early Evaluation of Ovarian Cancer Prognosis by Fusing Radiographic and Histopathologic Imaging Information
This project is testing a computer-made image marker that combines CT scans and pathology slides to tell which ovarian cancer patients are likely to benefit from chemotherapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma NIH-funded |
| Lab location | 1 site (Norman, United States) |
| Project ID | NIH-11256732 on NIH RePORTER |
What this research studies
Researchers will use CT scans and digitized pathology slides from ovarian cancer patients and train a machine-learning model to find image patterns linked to chemotherapy response. They will compute quantitative features from both radiographic and histopathology images (radiomics and pathomics) and fuse them into a single image marker. The marker will be built using a retrospective patient database and then tested prospectively to see if it predicts early treatment response. If the marker works, doctors could use it to personalize chemotherapy choices sooner.
Who could benefit from this research
Good fit: Ideal candidates are people with ovarian cancer who have pre-treatment CT scans and tumor tissue available for digital pathology, especially patients treated at or referred to the Stephenson Cancer Center.
Not a fit: Patients who lack CT scans or digitized pathology samples, or whose tumor types differ from those included in the study, may not receive direct benefit from this project.
Why it matters
Potential benefit: If successful, this could help identify earlier which patients will or will not respond to specific chemotherapies, allowing more personalized treatment decisions.
How similar studies have performed: Radiomics and pathomics approaches have shown promising early results in related cancers, but combining CT and histopathology into a validated clinical marker remains relatively novel.
Where this research is happening
Norman, United States
- University of Oklahoma — Norman, United States (Active)
Researchers
- Principal investigator: Qiu, Yuchen — University of Oklahoma
- Study coordinator: Qiu, Yuchen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.